FATE
Price
$2.33
Change
+$0.03 (+1.30%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
285.17M
27 days until earnings call
Intraday BUY SELL Signals
IMRA
Price
$14.59
Change
+$0.07 (+0.48%)
Updated
Jul 31 closing price
Net Assets
1.89M
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs IMRA

FATE vs IMRA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FATE vs. IMRA commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and IMRA is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
45
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATEIMRA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
37%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
37%
Advances
ODDS (%)
Bullish Trend 5 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (FATE: $2.30)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green while .

  • FATE’s FA Score: 1 green, 4 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 2 TA indicator(s) are bullish.

  • FATE’s TA Score: 2 bullish, 4 bearish.

Price Growth

FATE (@Biotechnology) experienced а -1.29% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

FATE is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
FATE
Daily Signal:
Gain/Loss:
IMRA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KLAG28.701.40
+5.14%
Leverage Shares 2x Long KLAC Daily ETF (KLAG)
VGIT56.64-0.02
-0.04%
Vanguard Intermediate-Term Treasury ETF (VGIT)
MPRO31.39-0.03
-0.10%
Monarch ProCap Index ETF (MPRO)
ENZL44.89-0.19
-0.41%
iShares MSCI New Zealand ETF (ENZL)
PML6.48-0.09
-1.37%
PIMCO Municipal Income FUND II

IMRA and

Correlation & Price change

A.I.dvisor tells us that IMRA and MRKR have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMRA and MRKR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRA
1D Price
Change %
IMRA100%
N/A
MRKR - IMRA
28%
Poorly correlated
-1.87%
FATE - IMRA
24%
Poorly correlated
-2.95%
AMLX - IMRA
23%
Poorly correlated
-3.51%
ABUS - IMRA
23%
Poorly correlated
-4.60%
ROIV - IMRA
22%
Poorly correlated
-2.93%
More